North America is expected to dominate the overall Short Bowel Syndrome Market throughout the forecast period

During the projection period, the Short Bowel Syndrome (SBS) Market was predicted to increase at a CAGR of roughly 29.8%. The rise in global frequency of GI illnesses such as volvulus, Inflammatory bowel disease (IBD), in particular Crohn's disease (CD), which predisposes individuals to develop SBS, and mesenteric ischemia are the most common causes for SBS among all age groups, requiring treatment.


Increased awareness efforts sponsored by organisations such as the Association of Gastrointestinal Motility, the Oley Foundation, and the SBS Cure Project, as well as an increase in government health-care spending, are expected to fuel market growth throughout the projection period.

Key Market Trends

GLP-2 Drug Therapy by Drug Class is Expected to Have the Largest Market Share During the Forecast Period During the forecast period, GLP-2 drug therapy is expected to hold the largest market share.The only medications available for treatment with the brand names Gattex and Revestive, introduced by Takeda and approved for sale in both the United States and Europe, account for the domination. Furthermore, the GLP-2 drug's patent exclusivity is expected to contribute to its high revenue share in the worldwide short bowel syndrome market.

Hospital pharmacies have the largest market share in terms of distribution channels, owing to the speedy implementation of therapy due to a large patient pool. Patients' preferences for parenteral nourishment, which is more expensive and unaffordable, as well as prescription medicines, contribute to a large proportion of the global Short Bowel Syndrome Market.

Throughout the forecast period, North America is predicted to dominate the entire Short Bowel Syndrome Market. The Gattex, the only glucagon-like peptide-2 (GLP-2) analogue approved in the United States to increase intestinal absorption in patients with SBS, is largely responsible for this supremacy..In addition, the rise in sedentary lifestyles has resulted in less time to focus on nutritious and healthy food, resulting in increasing intake of unhealthy and junk food and the resulting intestinal diseases, which is a major driver driving market expansion in the region.

Due to the large patient pools in China and India, as well as unregulated antibiotic consumption in India, the Asia Pacific region is expected to increase at the quickest rate throughout the projected period. In addition, research efforts and R&D investments in the region are expected to fuel the expansion of the SBS market in Asia Pacific, resulting in a substantial proportion of the global market.

The global market for short bowel syndrome is moderately competitive, with several major industrial participants. Some major businesses are forming strategic alliances and acquiring market-leading products, while others are extending their market share globally.

Comments

Popular posts from this blog

Continuous Glucose Monitoring (CGM) Devices Market -Dynamics and Forecast

YOU YES YOU!

Key Benefits of Breath Analyzer Market